Ratings by Barclays (Leon Wang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/25/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Rapt Therapeutics | RAPT | Downgrade | Equalweight (Overweight) |
7.98 (58.02) |
627.07% | Details | |
| 4/11/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2024 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/12/2023 | Moonlake Immunotherapeutics | MLTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/27/2023 | Moonlake Immunotherapeutics | MLTX | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/15/2023 | Moonlake Immunotherapeutics | MLTX | New Coverage | Equalweight (N/A) |
25.67 (18.27) |
-28.83% | Details | |
| 6/15/2023 | Rapt Therapeutics | RAPT | New Coverage | Overweight (N/A) |
21.54 (58.02) |
169.36% | Details | |
| 1/20/2023 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 1/12/2023 | Cincor Pharma Inc | CINC | Downgrade | Equalweight (Overweight) |
28.80 (29.06) |
0.9% | Details | |
| 12/7/2022 | Cincor Pharma Inc | CINC | New Coverage | Overweight (N/A) |
12.20 (29.06) |
138.2% | Details | |
| 12/7/2022 | Insmed | INSM | New Coverage | Overweight (N/A) |
18.98 (103.86) |
447.21% | Details |
